Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gallium Ga-68 Gozetotide

FDA-approved product (solution, intravenous), marketed as Gallium Ga 68 Gozetotide, Gozellix, Illuccix and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gallium Ga-68 Gozetotide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neuroimaging measurement

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gallium Ga-68 Gozetotide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gallium Ga-68 Gozetotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated

    NCT02920229 · start 2015-11

    Registered record
    Registry ID
    NCT02920229
    Conditions
    68Ga-PSMA HBED-PET/CT; Prostate Cancer
    Interventions
    68Ga- PSMA
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11
    Completion
    2020-10-09
    Enrolment
    1,230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition68Ga-PSMA HBED-PET/CT; Prostate Cancer
    Intervention68Ga- PSMA
    PhaseNot applicable
    Registry statusCompleted

  • 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

    NCT02488070 · start 2015-06

    Registered record
    Registry ID
    NCT02488070
    Conditions
    Recurrent Prostate Carcinoma
    Interventions
    Computed Tomography; Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx); Magnetic Resonance Imaging; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Carcinoma
    InterventionComputed Tomography; Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx); Magnetic Resonance Imaging; Positron Emission Tomography
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

    NCT02282137 · start 2015-05

    Registered record
    Registry ID
    NCT02282137
    Conditions
    Prostate Cancer
    Interventions
    68Ga-PSMA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2023-12
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Intervention68Ga-PSMA
    PhasePhase 2
    Registry statusUnknown

  • Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

    NCT04377152

    Registered record
    Registry ID
    NCT04377152
    Conditions
    Prostate Cancer; Prostate; Prostate Adenocarcinoma
    Interventions
    68Gallium-PSMA-11; Positron Emission Tomography (PET)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Prostate; Prostate Adenocarcinoma
    Intervention68Gallium-PSMA-11; Positron Emission Tomography (PET)
    PhaseNot recorded
    Registry statusApproved for marketing

  • Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer

    NCT05415228

    Registered record
    Registry ID
    NCT05415228
    Conditions
    Prostate Adenocarcinoma
    Interventions
    68Ga-PSMA-11
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    Intervention68Ga-PSMA-11
    PhaseNot recorded
    Registry statusNo longer available